phoslactomycin A: structure given in first source; isolated from Streptomyces nigrescens SC-273 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 6443962 |
MeSH ID | M0167942 |
Synonym |
---|
phoslactomycin a |
[3-[(1e,3e,9e)-8-(2-aminoethyl)-10-(3-ethyl-6-oxo-2,3-dihydropyran-2-yl)-5,8-dihydroxy-7-phosphonooxydeca-1,3,9-trienyl]cyclohexyl] 2-methylpropanoate |
122856-25-1 |
Q44188829 |
{[(1e,7e,9e)-3-(2-aminoethyl)-1-(3-ethyl-6-oxo-3,6-dihydro-2h-pyran-2-yl)-3,6-dihydroxy-10-{3-[(2-methylpropanoyl)oxy]cyclohexyl}deca-1,7,9-trien-4-yl]oxy}phosphonic acid |
DTXSID501043898 |
159991-67-0 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (55.56) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.73) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (22.22%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (77.78%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |